Adage Capital Partners
BTAI icon

Adage Capital Partners’s BioXcel Therapeutics BTAI Stock Holding History

Adage Capital Partners’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-29,086
Closed -$1.37M – 880
2023
Q4 		$1.37M Buy
29,086
+16,586
+133% +$922K ﹤0.01% 755
2023
Q3 		$506K Sell
12,500
-109,531
-90% -$11.1M ﹤0.01% 780
2023
Q2 		$13M Sell
122,031
-8,093
-6% -$2.69M 0.03% 517
2023
Q1 		$38.8M Buy
130,124
+75,436
+138% +$32.2M 0.09% 267
2022
Q4 		$18.8M Buy
+54,688
New +$13.2M 0.05% 442

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Adage Capital Partners's BTAI Position: Q1 2024 in Review

Adage Capital Partners sold out of BioXcel Therapeutics (BTAI) in Q1 2024, closing a stake of 29,086 shares — an estimated $1.37M sold.

Adage Capital Partners first reported a position in BTAI in Q4 2022 and held it in 5 quarters. The position peaked at $38.8M in Q1 2023. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • Adage Capital Partners reported no remaining BioXcel Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Adage Capital Partners sold 29,086 BioXcel Therapeutics shares in Q1 2024, an estimated $1.37M.
  • Adage Capital Partners first reported a position in BioXcel Therapeutics in Q4 2022 and held it in 5 quarters.
  • Adage Capital Partners's BioXcel Therapeutics position peaked at $38.8M in Q1 2023.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.